Determination of gallium in tumour-affected tissues by means of spectroscopic techniques

A receptor-based bioassay for quantitative detection of gallium

The detection of gallium in biological samples is required due to its role in the diagnosis of tumor and for possible treatment of malignancies. However, the use of purely instrumental techniques is unsuitable for detection of low levels of gallium in biological matrixes. We have synthesized new protein conjugates based on 4-(2-pyridylazo) ligands. The conjugates were successfully employed for the detection of gallium in biological matrixes using a nonantibody-based sandwich assay format. The recovery level obtained was between 97 and 101.3 with a relative standard deviation of less than 5%. The assay resulted in a detection limit of 5 x 10(-8) M and a remarkable selectivity for gallium(III) relative to other metals investigated. The new method provided adequate accuracy for gallium applicable for animal physiology and clinical toxicology.

Gallium distribution in several human brain areas

Gallium is an element of increasing biological interest: It is involved in problems related to environmental pollution (Ga compounds are used in electronics industry) and to clinical treatments (Ga radionuclides are employed to detect neoplastic lesions). Moreover, since its chemical behavior is similar to that of aluminum, gallium could play a role in the health effects attributed to this element. Data on naturally occurring Ga levels in human samples from healthy subjects are scanty; regarding the brain, the only reliable values available in the literature were published by Hamilton in 1972/73. In this work, the gallium distribution in several human brain areas, evaluated by radiochemical neutron activation analysis (RNAA), was found to be dishomogeneous. The element concentration determined in dry samples was, in any case, lower than the ppb level.